Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest Up 906.1% in November

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 672,100 shares, a growth of 906.1% from the October 31st total of 66,800 shares. Approximately 11.1% of the company’s shares are sold short. Based on an average trading volume of 1,420,000 shares, the short-interest ratio is presently 0.5 days.

Cyclacel Pharmaceuticals Trading Up 25.9 %

Shares of Cyclacel Pharmaceuticals stock traded up $0.09 during trading on Friday, hitting $0.43. 861,629 shares of the stock were exchanged, compared to its average volume of 695,894. Cyclacel Pharmaceuticals has a 1-year low of $0.32 and a 1-year high of $6.00. The stock has a market capitalization of $2.73 million, a price-to-earnings ratio of -0.04 and a beta of 0.56. The company has a fifty day moving average price of $0.72 and a 200-day moving average price of $1.31.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. Equities research analysts forecast that Cyclacel Pharmaceuticals will post -1.95 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on CYCC. Roth Capital cut shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals in a report on Saturday, November 23rd. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned approximately 9.18% of Cyclacel Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.